INZY Stock News & Analysis | Latest Updates

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INZY, SVT, HLGN on Behalf of Shareholders

NEW YORK, June 12, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Inozyme Pharma, Inc. (NASDAQ: INZY)'s...

June 12, 2025Lawsuits

INZY News

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INZY, SVT, HLGN on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INZY, SVT, HLGN on Behalf of Shareholders

Wells Fargo Maintains Equal-Weight on Inozyme Pharma, Lowers Price Target to $4

Wells Fargo Downgrades Inozyme Pharma to Equal-Weight, Announces $4 Price Target

Jefferies Downgrades Inozyme Pharma to Hold, Lowers Price Target to $4

Needham Downgrades Inozyme Pharma to Hold, Maintains Price Target to $12

Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:25:00 a.m. ET - Trading Halt: Halt News Pending

Needham Maintains Buy on Inozyme Pharma, Lowers Price Target to $12

Inozyme Pharma Q1 EPS $(0.44) Misses $(0.41) Estimate

HC Wainwright & Co. Reiterates Buy on Inozyme Pharma, Maintains $16 Price Target

Inozyme Pharma Publishes Paper Titled Phenotypic characterization of ENPP1 deficiency: generalized arterial calcification of infancy and autosomal recessive hypophosphatemic rickets type 2 In JBMR Plus

Needham Reiterates Buy on Inozyme Pharma, Maintains $15 Price Target

Raymond James Maintains Outperform on Inozyme Pharma, Lowers Price Target to $12

Piper Sandler Maintains Overweight on Inozyme Pharma, Lowers Price Target to $23

Needham Maintains Buy on Inozyme Pharma, Lowers Price Target to $15

HC Wainwright & Co. Reiterates Buy on Inozyme Pharma, Maintains $16 Price Target

Inozyme Pharma FY 2024 GAAP EPS $(1.62) Misses $(1.60) Estimate; Co. Prioritizes Activities To Support Planned Biologics License Application Filing For INZ-701 In ENPP1 Deficiency, Announces 25% Workforce Reduction

Inozyme Pharma To Present Interim Data For INZ-701 At CHOP Cardiology 2025

Piper Sandler Maintains Overweight on Inozyme Pharma, Lowers Price Target to $30

Wells Fargo Maintains Overweight on Inozyme Pharma, Lowers Price Target to $11

HC Wainwright & Co. Maintains Buy on Inozyme Pharma, Raises Price Target to $16

HC Wainwright & Co. Maintains Buy on Inozyme Pharma, Raises Price Target to $16

Inozyme Pharma Announces Interim Data For INZ-701 in Infants And Young Children wWth ENPP1 Deficiency, Showing Improvements From Baseline In Multiple Measures Of Disease

HC Wainwright & Co. Reiterates Buy on Inozyme Pharma, Maintains $14 Price Target

Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target

Inozyme Pharma Q3 EPS $(0.39) Beats $(0.44) Estimate